title: [Effect and mechanism of matrine on apoptosis of Raji cells].
abstract: OBJECTIVE
  To invest the effect and mechanism of matrine on apoptosis of human Burkitt's lymphoma Raji cells.
  
  
  METHODS
  Raji cells were cultured in vitro and treated by different final concentrations (0.4, 0.8, 1.6 mg/mL) of matrine or combined with SB203580 (p38 MAPK inhibitor) before matrine was added, then cocultured for 48 h, cell apoptosis rate was detected by Annexin V-FITC/PI double staining method and the P-p38 MAPK, Fas, FasL protein expresssion of Raji cells were evaluated by Western blot.
  
  
  RESULTS
  After cells were treated by matrine (0.4, 0.8, 1.6 mg/mL), the corresponding total apoptosis rate (15.77 +/- 0.53)%, (27.88 +/- 1.52)%, (48.08 +/- 2.87)%, had statistical significance compared with SB203580 groups (11. 48 +/- 0.64)%, (19.34 +/- 0.91)%, (33.98 +/- 1.26)% (P < 0.05 or P < 0.01), and control group (8.78 +/- 0.66)% (P < 0.05 or P < 0.01). As the concentration of matrine gradually increased,the protein expresssion levels of P-p38MAPK, Fas, FasL increased, and decreased after SB203580 were added, the correlation of P-p38MAPK and Fas, FasL was obvious.
  
  
  CONCLUSIONS
  Matrine can upregulation of Fas and FasL to promote the apoptosis of Raji cells, it may be related to p38MAPK Activation.
authors.affiliation: Department of Hematology, The Affiliated Yongchuan Hospital, Chongqing Medical University, Yongchuan Chongqing 402160, China. liuzhanshu@163.com
authors.forename: Zhan-shu
authors.initials: ZS
authors.lastname: Liu
authors.forename: Zhang-qin
authors.initials: ZQ
authors.lastname: Luo
authors.forename: Bo
authors.initials: B
authors.lastname: Xie
authors.forename: Qian-fu
authors.initials: QF
authors.lastname: Xue
authors.forename: Yue
authors.initials: Y
authors.lastname: Xiao
authors.forename: Ze-song
authors.initials: ZS
authors.lastname: Yang
authors.forename: Jian-bin
authors.initials: JB
authors.lastname: Chen
mesh_terms: D000470:Alkaloids / Q000008:administration & dosage / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D002051:Burkitt Lymphoma / Q000378:metabolism / Q000473:pathology*; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D053222:Fas Ligand Protein / Q000378:metabolism; D005434:Flow Cytometry; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D010766:Phosphorylation; D011725:Pyridines / Q000494:pharmacology*; D011807:Quinolizines / Q000008:administration & dosage / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects; D015854:Up-Regulation; D019014:fas Receptor / Q000378:metabolism; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D000093842:Matrines
chemical_list: D000470:Alkaloids; D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; C491901:FAS protein, human; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D007093:Imidazoles; D011725:Pyridines; D011807:Quinolizines; D019014:fas Receptor; D048051:p38 Mitogen-Activated Protein Kinases; C093642:SB 203580; D000093842:Matrines